Experimental drug REC-2282 targets NF2 brain tumors in early trial
NCT ID NCT05130866
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called REC-2282 in people aged 12 and older with progressive meningiomas (brain tumors) linked to NF2 gene mutations. Participants took the drug or a placebo three times a week in cycles. The goal was to see if the drug could slow tumor growth. The trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REC-2282 (also known as AR-42), a drug taken by mouth
What this could lead to
If it works, this could provide a new treatment option to slow or stop the growth of meningiomas in people with NF2, potentially delaying the need for surgery or radiation.
What could go wrong
This trial was terminated early with only 25 participants, so results are limited. The drug may not work better than placebo, and side effects are possible. More research is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Columbia University
New York, New York, 10032, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
House Institute
Los Angeles, California, 90057, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Nicklaus Children's Hospital
Miami, Florida, 33155, United States
-
Sarah Cannon Cancer Institute - HCA Midwest
Overland Park, Kansas, 66211, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Florida
Gainesville, Florida, 32611, United States
-
University of Minnesota / Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States